Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Absci official news RSS · 行业原文收录 · 来源发布：Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · 本站收录：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation
以上为带出处的原文节选，完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。